Screening for asymptomatic coronary artery disease in waitlisted kidney transplant candidates (CARSK)

Clinical practice guidelines recommend regular screening for asymptomatic coronary artery disease (CAD) in waitlisted kidney transplant candidates due to the high prevalence of cardiovascular disease in patients with end-stage kidney disease. However, the efficacy and cost-effectiveness of this practice have never been evaluated. This study aims to estimate the incremental costs and effects of no further screening compared with the current standard of care, which involves protocolised screening every 1-2 years for asymptomatic CAD after waitlist entry. A pre-trial model using current available published estimates is built to highlight areas of uncertainty to direct data collection during the main trial.

 

Collaborators:

Royal Prince Alfred Hospital, Charles Perkins Centre, University of Sydney School of Public Health, Auckland City Hospital, University of British Columbia Department of Medicine, University of Alberta Department of Medicine

Funded by:

NHMRC Project Grant APP1084454

Heart Foundation New Zealand

Canadian Institutes of Health Research

RL Morton supported by a NHMRC TRIP Fellowship APP1150989

Chief investigators:

Rachael L Morton, Anh Tran, Tracey Ying, Steve Chadban, Angela Webster, Helen Pilmore, Patrick Kelly, John Gill, Scott Klarenbach

Trial registration number:

ACTRN12616000736448

Contact:

healtheconomics@ctc.usyd.edu.au